Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE-ATTAIN-ADOLESCENTS Orforglipron Platform Trial in Adolescents With Obesity or Overweight
2024-514081-40-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Orforglipron once daily with Placebo once daily (2 arms). Primary endpoint: Percent change from baseline in BMI. Planned start Mar 2025; status: authorised.
02
Drugs
orforglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2024-514081-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514081-40-00.